PRNewswire

SHANGHAI, Nov. 4, 2024 /PRNewswire/ — BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral Abstract S

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: